Retour

FibroBiologics to Present at the BIO International Convention 2024

Calendar Calendar of Events

HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego, California. The presentation will occur on Tuesday, June 4, 2024, at 11:45 a.m. PDT in Theater 3.

GlobeNewswire Inc. • 07/05/2024 à 15:31:00
FibroBiologics, Inc. Common Stock
Address: 455 E. MEDICAL CENTER BLVD
Postal Code: 77598
City: HOUSTON
State: TX
Phone Number: 281-671-5152
Website: https://www.fibrobiologics.com
Status: Active
Company Info

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

List Date2024-01-31
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001958777
Composite figiBBG01K4MB400
Share Class figiBBG01K4MB4V6
Market Cap371,362,069 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees8
Share Class Shares Outstanding32720000
Weighted Shares Outstanding32719125
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
11.28
11.595
10.899
11.47
9.66
Variance
-3.03%
6.38%
-3.55%
14.38%
4.84%
Open
11.632
10.9
11.3
10.028
9.214
Highest
11.814
11.746
11.9
12.57
10.285
Lowest
11.809
11.735
11.895
12.57
10.285
History
PeriodVarhighestlowest
1 week
22.42%
10.285
10.285
1 month
7.38%
10.96
8.39
3 month
-23.33%
15.005
8.39
6 month
-62.4%
55
6.53
1 year
-62.4%
55
6.53
3 year
-62.4%
55
6.53
5 year
-62.4%
55
6.53
10 year
-62.4%
55
6.53
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
15:30
United States
-17800.000
15:30
United States
-60000.000
15:30
United States
53700.000
15:30
United States
-135800.000
★★
15:30
United States
4400.000
15:30
United States
215400.000
15:30
United States
-31400.000
15:30
United States
62600.000
15:30
United States
1300.000
15:30
United States
-9700.000
15:30
United States
199600.000
★★
15:30
United States
15:30
United States
15:30
United States
15:30
United States
News Stream
Stocks Annual Meetings & Shareholder Rights
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is July 1, 2024.
GlobeNewswire Inc. • 3d ago
Calendar Calendar of Events
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego, California. The presentation will occur on Tuesday, June 4, 2024, at 11:45 a.m. PDT in Theater 3.
GlobeNewswire Inc. • 1w ago
Health Health
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the Australian Patent Office (Patent Number 2017207445) covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today data from its latest study in a diabetes mouse model on the potential therapeutic efficacy of dermal fibroblast spheroids in treating chronic wounds. These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
GlobeNewswire Inc. • 1mo ago
Stocks Patents
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast cell-based technology for the potential treatment of Lupus.
GlobeNewswire Inc. • 1mo ago
See All

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT